In vitro discovery and optimization of a human monoclonal antibody that neutralizes neurotoxicity and lethality of cobra snake venom
Ledsgaard, L.; Laustsen, A. H.; Pus, U.; Wade, J.; Villar, P.; Boddum, K.; Slavny, P.; Masters, E. W.; Arias, A. S.; Oscoz, S.; Griffiths, D. T.; Luther, A. M.; Lindholm, M.; Leah, R. A.; Moeller, M. S.; Ali, H.; McCafferty, J.; Lomonte, B.; Gutierrez, J. M.; Karatt-Vellatt, A.
Show abstract
The monocled cobra (Naja kaouthia) is one of the most feared snakes in Southeast Asia. It is a highly dangerous species with a potent venom deriving its toxicity predominantly from abundant long-chain -neurotoxins. The only specific treatment for snakebite envenoming is antivenom, which is based on animal-derived polyclonal antibodies. Despite the lifesaving importance of these medicines over the past 120 years, and their ongoing role in combating snakebite disease, major limitations in safety, supply consistency, and efficacy creates a need for a new generation of improved treatments based on modern biotechnological techniques. Here, we describe the initial discovery and subsequent optimization of a recombinant human monoclonal immunoglobin G (IgG) antibody against -cobratoxin using phage display technology. Affinity maturation of the parental antibody by light chain-shuffling resulted in an 8-fold increase in affinity, translating to a significant increase in in vitro neutralization potency and in vivo efficacy. While the parental antibody prolonged survival of mice challenged with purified -cobratoxin, the optimized antibody prevented lethality when incubated with N. kaouthia whole venom prior to intravenous injection. This study is the first to demonstrate neutralization of whole snake venom by a single recombinant monoclonal antibody. Importantly, this suggests that for venoms whose toxicity relies on a single predominant toxin group, such as that of N. kaouthia, as little as one monoclonal antibody may be sufficient to prevent lethality, thus providing a tantalizing prospect of bringing recombinant antivenoms based on human monoclonal or oligoclonal antibodies to the clinic. One Sentence SummaryA recombinant human monoclonal immunoglobulin G antibody, discovered and optimized using in vitro methods, was demonstrated to neutralize the lethal effect of whole venom from the monocled cobra in mice via abrogation of -neurotoxin-mediated neurotoxicity.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Development of an Escape-resistant SARS CoV-2 Neutralizing Synthetic Nanobody 96%
- Opsonization by non-neutralizing antibodies can confer protection to SARS-CoV-2 despite Spike-dependent modulation of phagocytosis 95%
- Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment with TNF-alpha Antagonists 95%
Similar papers in this journal
- Enteric pharmacokinetics of monomeric and multimeric camelid nanobody single-domain antibodies 95%
- Sites of Vulnerability on Ricin B Chain Revealed through Epitope Mapping of Toxin-Neutralizing Monoclonal Antibodies 94%
- SARS-CoV2 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after infection 94%
Similar papers in this journal
- Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule 94%
- Broadly Reactive Anti-VHH Antibodies for Characterizing, Blocking, or Activating Nanobody-Based CAR-T Cells 94%
- Massively Multiplexed Affinity Characterization of Therapeutic Antibodies Against SARS-CoV-2 Variants 92%
Similar papers in this journal
- Discerning Specific Thrombolytic Activities and Blood Clot Degradomes of Diverse Snake Venoms with Untargeted Peptidomics 91%
- Phage Display Broadly Identifies Inhibitor-reactive Regions in von Willebrand Factor 91%
- Engineering a membrane-independent human prothrombinase through parsimonious mutation of factor Xa 90%
Similar papers in this journal
- Rapid Development of Neutralizing and Diagnostic SARS-COV-2 Mouse Monoclonal Antibodies 94%
- Heterologously secreted MbxA from Moraxella bovis induces a membrane blebbing response of the human host cell 93%
- Platelet Derived Growth Factor Receptor β (PDGFRβ) is a Host Receptor for the human malaria parasite adhesin TRAP 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.